{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:49:58Z","timestamp":1787878198705,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.urology.2006.01.001","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T14:04:08Z","timestamp":1149775448000},"page":"1199-1204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects"],"prefix":"10.1016","volume":"67","author":[{"given":"Fran\u00e7ois","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jos\u00e9e","family":"Cabanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Astruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2006.01.001_bib1","series-title":"Recommendations of the International Consensus Committee, Paris: June 1993","first-page":"553","article-title":"Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH)","author":"Cockett","year":"1993"},{"key":"10.1016\/j.urology.2006.01.001_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0090-4295(01)01402-9","article-title":"Guidelines for the diagnosis and treatment of benign prostatic hyperplasia","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.01.001_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5347(01)67269-0","article-title":"Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States","volume":"154","author":"Gee","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0090-4295(98)00054-5","article-title":"Overview of alpha-blocker therapy for benign prostatic hyperplasia","volume":"51","author":"Narayan","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.01.001_bib5","series-title":"The Third International Consultation on Benign Prostatic Hyperplasia (BPH), Monaco","first-page":"541","article-title":"Alpha-blockers therapy in benign prostatic hyperplasia. 3. Uroselectivity","author":"Andersson","year":"1996"},{"key":"10.1016\/j.urology.2006.01.001_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia","volume":"37","author":"van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","article-title":"Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.01.001_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia","volume":"92","author":"Roehrborn","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2006.01.001_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eursup.2003.11.002","article-title":"LUTS","volume":"2","author":"Moncada","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)02102-7","article-title":"Epidemiology of erectile dysfunction in four countries","volume":"61","author":"Nicolosi","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.01.001_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1464-410X.2003.04459.x","article-title":"The association between lower urinary tract symptoms and erectile dysfunction in four centres","volume":"92","author":"Boyle","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2006.01.001_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(03)00358-0","article-title":"Lower urinary tract symptoms and erectile dysfunction","volume":"44","author":"Braun","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-6109.2004.10104.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"1","author":"Lue","year":"2004","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2006.01.001_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0079-6468(02)41007-7","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors","volume":"41","author":"Haning","year":"2003","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.urology.2006.01.001_bib16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2003.09.023","article-title":"Time course of the interaction between tadalafil and nitrates","volume":"42","author":"Kloner","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urology.2006.01.001_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0735-1097(98)00656-1","article-title":"American College of Cardiology\/American Heart Association: ACC\/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease","volume":"33","author":"Cheitlin","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urology.2006.01.001_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.amjcard.2005.03.065","article-title":"Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)","volume":"96","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.urology.2006.01.001_bib19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","article-title":"Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men","volume":"172","author":"Kloner","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib20","doi-asserted-by":"crossref","first-page":"H37","DOI":"10.1016\/S1520-765X(02)90050-7","article-title":"Overview of the cardiovascular effects of tadalafil","volume":"4","author":"Emmick","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.urology.2006.01.001_bib21","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.clinthera.2004.11.006","article-title":"Role of the newer alpha-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms","volume":"26","author":"Lowe","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.urology.2006.01.001_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1464-410X.2005.05456.x","article-title":"Efficacy and safety of two doses (10 mg and 15 mg) of alfuzosin once daily in the treatment of symptomatic benign prostatic hyperplasia","volume":"95","author":"Nordling","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2006.01.001_bib23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations","volume":"170","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2006.01.001_bib24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0090-4295(98)00127-7","article-title":"Long-term evaluation of tamsulosin in benign prostatic hyperplasia","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2006.01.001_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1464-410X.2005.05347.x","article-title":"Alfuzosin 10 mg once daily improves sexual function in men with LUTS and concomitant sexual dysfunction","volume":"95","author":"van Moorselaar","year":"2005","journal-title":"BJU"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950600063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950600063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:43:18Z","timestamp":1758764598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042950600063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S009042950600063X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2006.01.001","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2006.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}